HALO · NASDAQ
Halozyme Therapeutics (HALO) Stock Price & Fundamentals
Halozyme Therapeutics (HALO) closed at $634.80 on Oct 9, 2026, up 0.45% from the previous close of $631.93.
Share price, past year
1Y +32.35%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $634.80 |
| Sep 30, 2026 | $614.68 |
| Aug 31, 2026 | $615.44 |
| Jul 31, 2026 | $624.19 |
| Jun 30, 2026 | $610.28 |
| May 29, 2026 | $573.06 |
| Apr 30, 2026 | $547.84 |
| Mar 31, 2026 | $505.28 |
| Feb 27, 2026 | $523.93 |
| Jan 30, 2026 | $495.74 |
| Dec 31, 2025 | $490.84 |
| Nov 28, 2025 | $473.56 |
| Oct 31, 2025 | $487.97 |
Key statistics
- Market cap
- $72.39B
- P/E (TTM)
- 185.6
- EPS (TTM)
- $3.42
- Revenue (TTM)
- $1.66B
- Net income (TTM)
- $413.60M
- Shares outstanding
- 114M
- Dividend yield
- —
- 52-week range
- $469.25 – $645.87
Halozyme Therapeutics's market cap is $72.39B, based on a share price of $634.80 and 114M shares outstanding as of Jun 30, 2026.
Financials
Halozyme Therapeutics reported revenue of $1.40B for fiscal 2025, up 37.55% from fiscal 2024.
Halozyme Therapeutics earned net income of $316.89M in fiscal 2025, a net margin of 22.7%.
Fiscal 2025 revenue was the highest in the 10 years shown.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $1.40B | +37.6% | $316.89M | 22.7% | $2.56 | $644.59M |
| FY2024ended Dec 31, 2024 | $1.02B | +22.4% | $444.09M | 43.7% | $3.43 | $468.37M |
| FY2023ended Dec 31, 2023 | $829.25M | +25.6% | $281.59M | 34.0% | $2.10 | $373.28M |
| FY2022ended Dec 31, 2022 | $660.12M | +48.9% | $202.13M | 30.6% | $1.44 | $235.30M |
| FY2021ended Dec 31, 2021 | $443.31M | +65.7% | $402.71M | 90.8% | $2.74 | $297.98M |
| FY2020ended Dec 31, 2020 | $267.59M | +36.5% | $129.09M | 48.2% | $0.91 | $52.95M |
| FY2019ended Dec 31, 2019 | $195.99M | +29.1% | −$72.24M | −36.9% | −$0.50 | −$89.46M |
| FY2018ended Dec 31, 2018 | $151.86M | −52.0% | −$80.33M | −52.9% | −$0.56 | −$54.16M |
| FY2017ended Dec 31, 2017 | $316.61M | +115.8% | $62.97M | 19.9% | $0.45 | $132.70M |
| FY2016ended Dec 31, 2016 | $146.69M | — | −$103.02M | −70.2% | −$0.81 | −$53.52M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $481.00M | $229.91M | $1.90 |
| Q1 FY2026ended Mar 31, 2026 | $376.71M | $150.05M | $1.22 |
| Q4 FY2025ended Dec 31, 2025 | $451.77M | −$141.59M | −$1.13 |
| Q3 FY2025ended Sep 30, 2025 | $354.26M | $175.23M | $1.43 |
| Q2 FY2025ended Jun 30, 2025 | $325.72M | $165.16M | $1.33 |
| Q1 FY2025ended Mar 31, 2025 | $264.86M | $118.10M | $0.93 |
| Q4 FY2024ended Dec 31, 2024 | $298.01M | $137.01M | $1.06 |
| Q3 FY2024ended Sep 30, 2024 | $290.08M | $137.01M | $1.05 |
Company profile
- Name
- Halozyme Therapeutics, Inc.
- Ticker
- HALO
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Biological Products, (No Diagnostic Substances)
- Headquarters
- 12390 El Camino Real, San Diego, CA 92130
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001159036
Recent SEC filings
- Sep 30, 2026
- Sep 22, 2026
- Sep 18, 2026
- Sep 16, 2026
- Aug 18, 2026
- Aug 6, 2026
- Aug 6, 2026
- Jul 2, 2026
Frequently asked questions
What is Halozyme Therapeutics's stock price?
Halozyme Therapeutics (HALO) closed at $634.80 on Oct 9, 2026, up 0.45% from the previous close of $631.93.
What is Halozyme Therapeutics's market cap?
Halozyme Therapeutics's market cap is $72.39B, based on a share price of $634.80 and 114M shares outstanding as of Jun 30, 2026.
How much revenue does Halozyme Therapeutics make?
Halozyme Therapeutics reported revenue of $1.40B for fiscal 2025, up 37.55% from fiscal 2024.
What is HALO's P/E ratio?
Halozyme Therapeutics's price-to-earnings ratio is 185.6, based on trailing twelve-month diluted EPS of $3.42.
Does Halozyme Therapeutics pay a dividend?
Halozyme Therapeutics's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Halozyme Therapeutics, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures